


# Pathophysiology of Acute Kidney Injury

Department of Medicine  
Brigham and Women's Hospital  
Distinguished Samuel A. Levine Professor of Medicine  
Harvard Medical School  
Past-President, American Society of Nephrology

## Joseph V Bonventre, MD, PhD



Harvard Medical School  
Medicine Residency @ Massachusetts General Hosp.  
Nephrology Fellowship @MGH  
Professor of Medicine@ HMS  
Chief Emeritus, Renal Division, BWH  
Founding Chief, Division of Engineering in Med. BWH

- Research focus: Kidney Injury and Repair

# DISCLOSURES

**Advisory Board/Consultant:** Praxis, Sarepta  
Mitsubishi Tanabe, Nimbus, Otsuke, Dynamicure,  
Verge Genomics

**Equity:** Innoviva, Pacific Biosciences

**Patents:** Co-Inventor on KIM-1 patents assigned to  
Partners Healthcare



# OBJECTIVES

To better understand

- The pathophysiology of ischemic and toxic acute kidney injury.
- The implications of this pathophysiology for progression to chronic kidney disease and approach to therapy.



# Pathophysiology of Acute Kidney Injury

- > Definitions
- > Pathophysiology of Injury
  - Tubules
  - Blood Vessels
  - Inflammation
- > Maladaptive Repair leading to Chronic Kidney Disease
- > Therapeutic Approaches


# KDIGO Definition of AKI

Acute kidney injury is defined when one of the following criteria is met:

- > Serum creatinine rises by  $\geq 26\mu\text{mol/L}$  (0.3 mg/dl) within 48 hours or
- > Serum creatinine rises  $\geq 1.5$  fold from the reference value, which is known or presumed to have occurred within 7 days or
- > Urine output is  $< 0.5 \text{ ml/kg/hr}$  for  $>6$  consecutive hours

KDIGO = **K**idney **D**isease to **I**mprove **G**lobal **O**utcomes

# Hospital survival, stratified by KDIGO stages of acute kidney injury



Chertow  
Burdick  
Honour  
Bonventre  
Bates  
JASN 16:  
3365-70, 2005

# Risk Factors for Acute Kidney Injury

AKI Risk Factors	
Older age	Shock
Diabetes	Sepsis
Hypertension	Nephrotoxins
Chronic kidney disease	(NSAIDs, ARB, ACEi, contrast)
Cardiovascular disease	Surgery
Chronic liver disease	Hyperuricemia
Chronic obstructive pulmonary disease	Hypoalbuminemia
HIV infection	Hyperglycemia
Obesity	Anemia



# What Has Held Up Progress

Definition of AKI relies on  $\Delta$  sCreat


- Serum creatinine rises by  $\geq 26\mu\text{mol/L}$  (0.3 mg/dl) within 48 hrs or
- Serum creatinine rises  $\geq 1.5$  fold from the reference value, which is known or presumed to have occurred within one week, or
- Urine output is  $< 0.5\text{ml/kg/hr}$  for  $> 6$  consecutive hours

BUT

Acute kidney injury  $\neq$  Acute tubular/interstitial injury


We want biomarkers that measure tubular-interstitial injury

# Renal Functional Reserve




Modified from  
Sharma, Mucino and Ronco  
Nephron Clin Prac  
127:94-100, 2014

# Acute Kidney Injury



# Mean Urinary KIM-1 and NAG Levels During Cisplatin Treatments In Patients with Testicular Cancer




# FDA Qualified Safety Biomarker Panel

Acronym	Name (Unique ID (Uniprot))	Description
CLU	Urinary Clusterin (P10909)	A heterodimeric highly conserved secreted glycoprotein expressed in the proximal and distal tubules, glomerulus and collecting duct.
CysC	Cystatin-C (P01034)	A small serum protein produced by all nucleated cells and found in most tissues and body fluids. CysC is freely filtered by the glomerulus and completely reabsorbed and catabolized in healthy renal tubular epithelium.
KIM-1	Kidney Injury Molecule -1 (Q96D42)	A type I transmembrane glycoprotein containing an ectodomain consisting of an immunoglobulin-like domain and a mucin domain that is strongly induced by ischemic and toxic insults to the kidney.
NAG	N-acetyl-beta-D-glucosaminidase (O60502)	A large lysosomal enzyme with two isoforms and is mainly expressed in proximal tubules.
NGAL	Neutrophil gelatinase-associated lipocalin (P80188)	Expressed in various tissues at low levels with upregulated transcription in tubuloepithelial cells following ischemic and nephrotoxic kidney injuries.
OPN	Osteopontin (P10451)	A highly acidic glycoprotein expressed by many tissues that acts as a macrophage adhesion and chemotactic molecule.

# Pathophysiology of Acute Kidney Injury


- > Definitions
- > Pathophysiology of Injury
  - Tubules
  - Blood Vessels
  - Inflammation
- > Maladaptive Repair leading to Chronic Kidney Disease
- > Therapeutics Approaches

# Some mechanisms involved in initial tissue injury and subsequent repair of the kidney after acute kidney injury






# Endothelial and Epithelial Injury, Inflammation and AKI






# Simplified Pathobiology of AKI



Normally a cell can undergo >1 million DNA changes per day.

(Lodish et al, Mol Bio Cell)

# Downstream of DNA Repair Pathways





# Multimodal single-cell and Spatial Atlas: Integrated Transcriptomics, Epigenomic and Imaging Data from Three Major Consortia (HuBMAP, KPMP and Human Cell Atlas)



- ❑ Putative adaptive or maladaptive repair signatures within the epithelial segments ...may reflect a failure to complete differentiation and tubulogenesis.
- ❑ Epithelial repair states have elevated cytokine production, increased interactions with the distinct fibrotic and inflammatory cell types, and expression signatures linked to senescence and progression to end-stage kidney disease.
- ❑ Failure of these cells to complete tubulogenesis...might ultimately contribute to a progressive decline in kidney function.
- ❑ The high-cytokine-producing nature of these cells may further contribute to kidney disease through promotion of fibrosis.

# Endothelial and Epithelial Injury and Glycocalyx Disruption in AKI

Normal




Post AKI







# Nephron, corticomedullary oxygen gradient, and microvascular anatomy.



# Perfusion Maps of the Mouse Kidney using Contrast-Enhanced Ultrasound



Pre-I/R      15 min    30 min    45 min    60 min    24 hr

---

Post-I/R

# Kidney Pathology in Patients Dying of Sepsis

Statement from Literature  
That Underestimates the  
Importance of Tubular Injury  
In Sepsis induced AKI


“Renal tubular injury is common in sepsis but presents focally: Most renal tubular cells appear normal. The degree of cell injury and death does not account for severity of sepsis-induced organ dysfunction.”

- Proximal tubule vacuolization: 77% of septic patients
- KIM-1 expression: 32.3% corticomedullary junction  
19.6% cortical labyrinth tubules

Takasu....Hotchkiss Am J Resp Crit Care Med.  
187:509-517, 2013


Beeuwkes and Bonventre,  
Am. J. Physiol., 1975

Complexity of Proximal Tubule






# Fluid may be very bad for AKI






# Effects of Fluid Overload on Organ Systems



# Pathophysiological Features of Cardiac Damage after Acute Kidney Injury



# Pathophysiology of Acute Kidney Injury

- > Definitions
- > Pathophysiology of Injury
  - Tubules
  - Blood Vessels
  - Inflammation
- > Maladaptive Repair leading to Chronic Kidney Disease
- > Therapeutics Motivated by Pathobiology

AKI Leads to CKD


**AKI**



**CKD**


CKD Predisposes to AKI

# Natural history of acute kidney injury (AKI).







# Meta-analysis of the risk of Chronic Kidney Disease after AKI



# Maladaptive repair of AKI leads to CKD




# AKI and Progression of Diabetic Kidney Disease



Yu and Bonventre  
Adv. Chronic Kid  
Dis 2018




# Meta-analysis SGLT2i Effects on Acute Kidney Injury (13 Trials)




The Neuffield Department of Population Health Renal Studies Group and The SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists Consortium. Lancet 400: 1788-1801, 2022


# SGLT2 Inhibitor Effects on Hemodynamics and Oxygenation




Bergman et al (U. of Iowa)




## SGLT2 inhibitors



Empagliflozin



Canagliflozin



Dapagliflozin

Other SGLT2i

## Potential Protective Mechanisms

AMPK



Autophagy



KIM-1



Apoptosis



p53 / p21



Cellular Senescence



GSK-3 $\beta$



Inflammatory Cytokines



HIF-1 $\alpha$   
HE4 / NF- $\kappa$ B



Fibrosis



NRF2/HO-1



ROS



PINK1



Mitophagy



CoRL




Glomerular Regeneration




Renoprotective effect

Injury



Early Adaptive Repair


CKD



# Effects of Glucose Uptake on Proximal Tubular Metabolism

SGLTi will Inhibit these maladaptive changes

GLUCOSE GLUCOSE Proximal Tubules



Normally a cell can undergo >1 million DNA changes per day.

(Lodish et al, Mol Bio Cell)

# Pathophysiology of Acute Kidney Injury

- > Definitions
- > Pathophysiology of Injury
  - Tubules
  - Blood Vessels
  - Inflammation
- > Maladaptive Repair leading to Chronic Kidney Disease
- > Therapeutics Approaches

# Kidney Replacement Therapy in Critically ill Patients

## Which Statement is false

- ☐ In the absence of severe AKI complications medical management has been shown to be inferior to KRT
- ☐ Higher effluent flows ( $>20$ - $25$  ml/kg/hr) do not increase survival
- ☐ Greater frequency than 3x/week does not improve outcome
- ☐ No strong data that continuous therapy is better than intermittent

# Indications for Kidney Replacement Therapy in Critically ill Patients

## **Urgent indications in patients with AKI**

Refractory, severe hyperkalemia†

Refractory, severe metabolic acidosis†

Refractory, severe pulmonary edema†

Uremic complications: pericarditis, bleeding, and encephalopathy‡

## **Urgent indications in patients without AKI**

Severe intoxication due to lithium, toxic alcohol poisoning (especially from ethylene glycol or methanol), metformin, or salicylate

## **Nonurgent indications**

Persistent, severe AKI with blood urea nitrogen level >12 mg/dl, oliguria or anuria for more than 72 hr, or both§

## **No indications**

Severe AKI (KDIGO stage 3) in the absence of complications¶

Sepsis in the absence of complicated AKI

# Fluid Management in AKI

Which of the following is False

- A. Buffered solutions (Ringer's lactate, Hartmann's solution, Plasma Lyte) are recommended for patients at risk of AKI who are not hypochloremic.
- B. Albumin decreases fluid requirements for resuscitation, improves survival and reduces the need for RRT compared to crystalloid.
- C. Starch, gelatin and dextrans should be avoided.
- D. 0.9% saline can cause vasoconstriction



# Fluid Therapy for Acute Kidney Injury

**General Principle:** In AKI oliguria is not an indication for fluid administration. Intravascular hypovolemia should be the only indication. Optimal fluid composition has not been defined.

**Crystalloids:** Hyperchloremia associated with 0.9% saline may cause renal vasoconstriction

Buffered solutions (Ringer's lactate, Hartmann's solution, Plasma Lyte) are recommended for patients at risk of AKI who are not hypochloremic.

0.9% saline is recommended for hypovolemic, hypochloremic patients (with close monitoring of chloride)

**Colloids:** Gelatin based fluids should be avoided

Albumin does not provide a survival benefit compared with crystalloid.

Albumin decreases fluid requirements for resuscitation but does not reduce the need for RRT.

Starch should be avoided.

# Some Currently Studied Therapeutics for AKI and Pathobiology Targeted

## Anti-inflammatory

Alkaline Phosphatase  
 $\alpha$ -MSH analogs (ABT-719)  
Vitamin D  
DPP-4 Inhibitors  
CD28 antagonists  
Sphingosine-1-P analogs  
Anti-IL6 antibodies  
Heme arginate  
Mesenchymal Stem Cells  
Extracellular Vesicles

## Improve Mitochondria

Nicotinamide Adenine Dinucleotide  
Cardiolipin

## Anti-oxidants

Iron chelators  
NGAL  
Heme arginate  
Bardoxalone  
Propofol  
Curcumin  
 $\alpha$ -lipoic acid

## Vasoactive

Angiotensin II  
Levosimendan

## Senolytic

Navitoclax

## Facilitate Regeneration

Hepatocyte Growth Factor  
BMP receptor agonists


## ? Cell Cycle/ ? Cell Death

P53 siRNA

# Cardiac Surgery Patients without AKI within 7 days of Randomization

**Intervention**  
Balanced Amino Acids (2g/kg) for 72 hr or ICU discharge or CRRT or death.  
  
Median infusion 30h

**Endpoint**  
AKI by KDIGO  
  
Death 2.8% in each group



## No. at Risk

Amino acid group	1759	1739	1516	1397	1372	1351	1334	1285
Placebo group	1752	1728	1436	1289	1270	1256	1246	1197

# Take Home Messages

To Develop New Therapies for Human AKI

We need:

- ◆ More efficient ways to select high risk patients  
-GFR, Renal Reserve, with other clinical features
- ◆ Qualification of blood and urine biomarkers using better ways to determine kidney injury than by using creatinine
- ◆ New non-invasive tools to interrogate metabolism, cellular repair response and pathobiology, particularly endothelial pathology
- ◆ Animal models which incorporate underlying co-morbidities that characterize our patients.
- ◆ Human tissue obtained at well characterized stages of early AKI
- ◆ Human tissue models to mimic AKI and AKI►CKD
- ◆ Cell type specific characterization of the human tissue
- ◆ Better understanding of effects of genetics predisposition to AKI and propensity to maladaptive repair humans

# References

Barasch J, Zager R, Bonventre JV. [Acute kidney injury: a problem of definition](#). Lancet 389: 779-781, 2017

Yu SM, Bonventre JV. [Acute kidney injury and maladaptive tubular repair leading to renal fibrosis](#). Curr Opin Nephrol Hypertens. 29:310-318, 2020

Lake BB et al. [An atlas of healthy and injured cell states and niches in the human kidney](#). Nature 619: 585-594, 2023

Ostermann M et al. [Acute Kidney Injury](#). Lancet 405: 241-256, 2025

Thank You